Evidence map›Paper›PMID 30607332›Full record

ArticleAdvanced pharmaceutical bulletin2018

Anti-CD24 bio Modified PEGylated Gold Nanoparticles as Targeted Computed Tomography Contrast Agent.

Mona Fazel Ghaziyani, Mohammad Pourhassan Moghaddam, Daryoush Shahbazi-Gahrouei, Mostafa Ghavami, Ali Mohammadi, Mehran Mesgari Abbasi, Behzad Baradaran

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced pharmaceutical bulletin, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Mona Fazel GhaziyaniDepartment of Medical Physics, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.ORCID 0000-0003-4005-7434
Mohammad Pourhassan MoghaddamImmunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Daryoush Shahbazi-GahroueiDepartment of Medical Physics, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.ORCID 0000-0002-8538-1898
Mostafa GhavamiDepartment of Radiology, Paramedical School, Tabriz University of Medical Sciences, Tabriz, Iran.
Ali MohammadiImmunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Mehran Mesgari AbbasiDrug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Behzad BaradaranImmunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.ORCID 0000-0002-8642-6795
Tabriz University of Medical Sciences · IRIsfahan University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Cancer imagingCD24 antibodyComputed tomographyGold nanoparticle

Identifiers

PMID30607332
PMCPMC6311644
OpenAlexW2905351482

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.